Menu
Search
|

Menu

Close
X

Aytu BioScience Inc AYTU.OQ (NASDAQ Stock Exchange Capital Market)

1.33 USD
-0.01 (-0.75%)
As of Feb 16
chart
Previous Close 1.34
Open 1.35
Volume 4,721
3m Avg Volume --
Today’s High 1.35
Today’s Low 1.30
52 Week High 6.35
52 Week Low 1.23
Shares Outstanding (mil) 4.40
Market Capitalization (mil) 5.90
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
3
FY16
3
FY15
0
EPS (USD)
FY18
-2.650
FY17
-54.431
FY16
-288.371
FY15
-303.897
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
1.53
8.57
Price to Book (MRQ)
vs sector
2.16
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
0.00
15.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.85
Return on Investment (TTM)
vs sector
-139.09
13.54
Return on Equity (TTM)
vs sector
-295.08
14.80

EXECUTIVE LEADERSHIP

Joshua Disbrow
Chief Executive Officer, Director, Since 2016
Salary: $246,000.00
Bonus: $202,500.00
David Green
Chief Financial Officer, Treasurer, Secretary, Since 2017
Salary: --
Bonus: --
Jarrett Disbrow
Chief Operating Officer, Since 2016
Salary: $218,000.00
Bonus: $5,000.00
Michael Macaluso
Director, Since 2015
Salary: --
Bonus: --
Gary Cantrell
Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

373 Inverness Pkwy Ste 206
ENGLEWOOD   CO   80112-5898

Phone: +1720.4376580
Site: aytubio.com/

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.

SPONSORED STORIES